The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria.
The aim of present study was to determine if factor V Leiden (FVL) mutation and angiotensin converting enzyme insertion/deletion (ACE I/D) polymorphism are associated with diabetic nephropathy (DN) among Kurdish population from Western Iran. This case-control study comprised 144 unrelated adult type 2 diabetic mellitus patients (T2DM) including 72 patients with microalbuminuria and 72 age and sex matched patients without nephropathy. The ACE I/D polymorphism and FVL mutation were detected by polymerase chain reaction (PCR) and PCR-RFLP, respectively. The frequency of FVL G1691A and ACE D allele in T2DM patients with microalbuminuria were 1.6 and 57%, respectively and in normoalbuminuric T2DM patients were 4.9 and 58.3%, respectively (P > 0.05). ACE genotypes affected on serum ACE activity and a better response to ACE inhibitor therapy (captopril) compared to angiotensin II receptor antagonist (losartan) was obtained with significant reduction of ACE activity in diabetic patients without nephropathy carrying DD genotype. However, the beneficial effect of losartan therapy was observed in microalbuminuric patients with II genotype compared to ID and DD genotypes.
Rahimi
Zohreh
Z
The Rhazes Center for Research in Family Health and Sexual Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. zrahimi@kums.ac.ir
Felehgari
Vahid
V
Rahimi
Mehrali
M
Mozafari
Hadi
H
Yari
Kheirollah
K
Vaisi-Raygani
Asad
A
Rezaei
Mansour
M
Malek-Khosravi
Shohreh
S
Khazaie
Habibolah
H
D000419:Albuminuria / Q000150:complications* / Q000235:genetics; D000483:Alleles; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D003928:Diabetic Nephropathies / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D005165:Factor V / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007492:Iran; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009154:Mutation; D007703:Peptidyl-Dipeptidase A / Q000097:blood* / Q000235:genetics*; D011110:Polymorphism, Genetic; D016896:Treatment Outcome
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; C095381:factor V Leiden; D005165:Factor V; D002216:Captopril; C488034:ACE protein, human; D007703:Peptidyl-Dipeptidase A; D019808:Losartan